. home.aspx



Trial could unlock asthma use for GSK’s Trelegy

May 03, 2019 / Phil Taylor

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market.

Top-line results from the CAPTAIN study have shown that Trelegy (fluticasone furoate/umeclidinium/vilanterol) works better than GSK’s two-drug combo Relvar/Breo (fluticasone furoate/vilanterol) at improving lung function in patients living with uncontrolled asthma who struggle to breathe.

The results aren’t all positive – Trelegy wasn’t able to improve on Relvar/Breo when it came to reducing asthma exacerbations and two other doses of Trelegy didn’t perform better than the two-drug regimen on lung function scores.

Nevertheless, GSK R&D chief Hal Barron thinks the triple therapy is still on track for a regulatory filing in uncontrolled asthma once the full dataset is available, and that could extend Trelegy’s indications bey...